Cohance Lifesciences

Cohance Lifesciences reported FY26 revenue of ₹22.68BCurrent reported value: ₹22.68B. No comparable prior figure is available in the source record., down 13% YoYCurrent reported value: 13% YoY. No comparable prior figure is available in the source record., with adjusted EBITDA margin of 21%Current reported value: 21%. No comparable prior figure is available in the source record. (standalone 24.6%). The CDMO segment was hit by destocking of two large commercial molecules (~₹260Cr impact) and delayed reloads, while API Plus declined 8Current reported value: 8. No comparable prior figure is available in the source record.% due to shipment delays and Nacharam site disruption. Specialty Chemicals fell 2.1% on program phasing. Management guided Q1 FY27 as the low point, with recovery from H2 driven by order conversion, new commercial launches (two molecules already commercialized, two more expected), and a strengthened phase 3 pipeline of 10 programsCurrent 10 programs. Reported change: +1 program YoY.. Key risks include Middle East logistics cost inflation (100-150bps gross margin impact in Q1), delayed recovery of destocked molecules, and execution at NJ Bio (breakeven >2 years away). New CEO Omar Gora is focused on strategic blueprint, operational rigor, and deepening customer relationships.